Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy
Phase 3
Completed
NCT00780910
| Condition | Chronic Hepatitis C |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Tanabe Pharma Corporation |
|---|
| Status | Completed |
|---|
| Enrollment | 109 participants |
|---|
| Interventions | MP-424, Ribavirin, Peginterferon Alfa-2b |
|---|
| Start date | Nov, 2008 |
|---|
| Completion date | Oct, 2010 |
|---|
| Results posted | Aug 20, 2012 |
|---|
Summary
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b (PEG-IFN) and Ribavirin (RBV) in patients with (Genotype 1) hepatitis C, who relapsed after previous treatment.
The Percentage of Subjects Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)
After 24 weeks of follow-up · percentage of subjects achieving SVR
| MP-424 | 88.1 percentage of subjects achieving SVR |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.